Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 24 Issue 3, March 2024

Membrane organisers, inspired by the Review on p193.

Cover design: Simon Bradbrook

Research Highlights

Top of page ⤴

Journal Club

Top of page ⤴

Reviews

  • This Review covers the biology of anti-cytokine autoantibodies and their varied roles in causing, preventing and treating diseases. Recent reports of anti-type I interferon autoantibodies in critical COVID-19 have led to renewed interest in this topic, which offers fascinating insights into the reversibility of immune tolerance and the origins of autoimmunity in otherwise healthy individuals.

    • Aristine Cheng
    • Steven M. Holland
    Review Article
  • The MHC class I-related protein 1 (MR1) presents specific small molecule antigens to MR1-restricted T (MR1T) lymphocytes. These cells play an important role in infection and cancer, and strategies to target these cells are of considerable therapeutic interest. In this Review, McWilliam and Villadangos provide a comprehensive description of the antigen presentation pathway of MR1, which is fundamental for the understanding of MR1-mediated immunity and the potential therapeutic manipulation of MR1T cells.

    • Hamish E. G. McWilliam
    • Jose A. Villadangos
    Review Article
  • The families of tetraspanins and galectins are essential for the organization of molecules on the surface of lymphocytes, and deficiencies in specific family members can lead to impaired immunity, tumour development and autoimmunity. This Review investigates the molecular mechanisms of membrane organization by tetraspanins and galectins, specifically their role in B cell and T cell proliferation, survival and migration, as well as in antibody production and T cell polarization, and discusses potential therapeutic opportunities.

    • Laia Querol Cano
    • Vera-Marie E. Dunlock
    • Annemiek B. van Spriel
    Review Article
  • Personalized neoantigen vaccines offer the potential to boost immune response a patient against their specific cancer antigens. Here, Katsikis, Ishii and Schliehe discuss the challenges that currently limit this therapeutic approach, including those related to neoantigen selection and adjuvants, and post-vaccine challenges such as the immunosuppressive tumour microenvironment. Moreover, they consider solutions that could help to overcome these obstacles.

    • Peter D. Katsikis
    • Ken J. Ishii
    • Christopher Schliehe
    Review Article
Top of page ⤴

Amendments & Corrections

Top of page ⤴

Search

Quick links